Results 81 to 90 of about 35,844 (219)

2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management

Internal Medicine Journal, EarlyView.
Abstract Direct oral anticoagulants (DOACs) are widely prescribed to prevent and treat venous and arterial thromboembolism, supported by published evidence, and are preferred over warfarin in many guidelines. Although the risk of major bleeding, in particular intracranial haemorrhage (ICH), is decreased with DOACs, gastrointestinal bleeding is ...
Huyen A. Tran, Eileen Merriman, Ross Baker, Jennifer Curnow, Laura Young, Chee Wee Tan, Simon McRae, Sanjeev D. Chunilal   +7 more
wiley   +1 more source

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment

Vascular Health and Risk Management, 2013
Andreas Clemens,1 Mandy Fraessdorf,2 Jeffrey Friedman31Corporate Division Medicine, TA Cardiovascular, 2Medical Data Services, Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany; 3Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT ...
Clemens A, Fraessdorf M, Friedman J
doaj  

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +1 more source

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

The Atrial Fibrillation Registry (The FLOW‐AF Registry): Insights From the United Arab Emirates—Patient Characteristics, Treatment, and One‐Year Outcomes

Journal of Cardiovascular Electrophysiology, Volume 36, Issue 4, Page 813-823, April 2025.
ABSTRACT Background The epidemiological landscape and treatment efficacy of atrial fibrillation (AF) in the Middle East, notably in the United Arab Emirates (UAE), remain under‐explored, presenting a distinct demographic and clinical pattern compared to Western populations.
Moutaz El Kadri, Khalid AlMuti, Amrish Agrawal, Nooshin Bazargani, Mohamed Fathy Soliman Gamaleldin, Haytham Mohamed Ahmed, Omneya Hassanain, Natasha Khalife, Ghazi Radaideh, Mohamed Magdy, Wael A. Almahmeed   +10 more
wiley   +1 more source

Dabigatran experience in primary and secondary prevention of cardioembolic stroke

Неврология, нейропсихиатрия, психосоматика, 2013
The review of novel oral anticoagulants (dabigatran, rivaroxaban and apixaban) in stroke prevention and also own data of administration of dabigatran in primary and secondary prevention of ischemic stroke in 45 patients with cerebrovascular diseases are ...
Maksim Alekseyevich Domashenko, M Yu Maksimova, D Z Korobkova, M E Gafarova   +3 more
doaj   +1 more source

Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C [PDF]

, 2014
AIMS: Dabigatran is largely cleared by renal excretion. Renal function is thus a major determinant of trough dabigatran concentrations, which correlate with the risk of thromboembolic and haemorrhagic outcomes.
Berit P. Jensen, Daniel F. B. Wright, David M. Patterson, Evan J. Begg, Mary C. Wallace, Mei Zhang, Murray L. Barclay, Paul K. L. Chin, Rebecca L. Roberts   +8 more
core   +1 more source

Vonoprazan or Proton Pump Inhibitor for Gastric Endoscopic Submucosal Dissection in Patients Taking Antithrombotic Agents

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Delayed bleeding is a major concern after gastric endoscopic submucosal dissection (ESD), especially in patients taking antithrombotic agents. The aim of this study was to evaluate the superiority of vonoprazan (VPZ) over proton pump inhibitor (PPI) in preventing delayed bleeding after gastric ESD in patients taking ...
Hiroyuki Shibata, Toshihisa Fujiyoshi, Noboru Kawata, Tomohiko Obayashi, Masaya Esaki, Masakazu Kikuchi, Naohiro Yoshida, Tsuguo Kamioka, Yoji Sasaki, Makoto Kobayashi, Muneyori Okita, Shigeyuki Matsui, Kazuhiro Furukawa, Masanao Nakamura, Naomi Kakushima, Mitsuhiro Fujishiro, Hiroki Kawashima   +16 more
wiley   +1 more source

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Trauma Case Reports, 2021
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle, Christopher Rugg, Stefan Schmid, Dietmar Fries, Elgar Oswald   +4 more
doaj  

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

Health and Quality of Life Outcomes, 2017
Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource ...
Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu, George Andrews   +9 more
doaj   +1 more source